More from @HanCardiomd

Henry Han, MBBS, MD

@HanCardiomd

30 Aug

@ESC_Journals

Iron deficiency as a therapeutic target in heart failure - new evidence, new guidelines

New evidence from AFFIRM-AHF ‒ implications for clinical practice with ⬆️QoL
#ESCCongress @ESC_Journals @escardio @ShelleyZieroth @hvanspall @DrNasrien @SilCastelletti @DrMarthaGulati

@ESC_Lavinia

New evidence from AFFIRM-AHF ‒ implications for clinical practice on cost effectiveness and QoL

#ESCCongress @ESC_Lavinia @escardio @ESCardioNews @ShelleyZieroth @JavedButler1 @rachkataria @AndreasGevaert @AndrewJSauer @pabeda1 @BSHeartFailure @FH_Verbrugge @DrRyanPDaly

@JavedButler1

Very insightful presentation by @JavedButler1 on New evidence from meta-analyses ‒ lessons to learn on the benefits of intravenous ferric carboxymaltose in HF

#ESCCongress @JavedButler1 @DrNasrien @MihaiTrofenciuc @pabeda1 @AndrewJSauer @NMHheartdoc @hvanspall @MajaCikes

Read 5 tweets

Henry Han, MBBS, MD

@HanCardiomd

29 Aug

@escardio

Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt? - Joint with (ISCP)

Prevention of thromboembolism in COVID-19
#ESCCongress @escardio @ESC_Lavinia @Steph_Achenbach @susannaprice @mmamas1973 @fhussain73 @DrJennHaythe md

@escardio

Recommendation for thrombophylaxis in COVID19

#ESCCongress @escardio @ESCardioNews @ESC_Lavinia @mmamas1973 @fhussain73 @susannaprice @JJcolemanMD @DrJennHaythe @PeterHotez @VirusesImmunity @bchTicTocDoc @AnastasiaSMihai

@escardio

COVID-19 #myocarditis and myocardial injury: active participant or innocent bystander?
#ESCCongress
@escardio @DrJennHaythe @AnastasiaSMihai @CMichaelGibson @mmamas1973 @EricTopol @ErinMichos @DBelardoMD @fhussain73 @VirusesImmunity @fhussain73 @pabeda1 @JGrapsa

Read 8 tweets

Henry Han, MBBS, MD

@HanCardiomd

28 Aug

@escardio

FIGARO -DKD

FIGARO-DKD Finds Finerenone Offers CV Benefits in Mild to Moderate Kidney Disease With T2D; Cuts HF Hospitalization 29% @escardio #ESCCongress @JJheart_doc @AnastasiaSMihai @ESC_Journals @ShelleyZieroth @mmamas1973 @hvanspall @JavedButler1 @DrNasrien @aayshacader

@escardio

A statistically significant 13% lower risk among those treated with finerenone, a benefit that was driven by a reduction in HHF (HR 0.71; 95% CI 0.56-0.90)

@escardio #ESCCongress @ShelleyZieroth @hvanspall @mmamas1973 @AnastasiaSMihai @DrNasrien @lamcardio @JavedButler1

@escardio

The combined patient-level analysis of FIGARO-DKD and FIDELITY-DKD included 13,171 patients with #T2DM of whom 40% had preserved kidney function as defined by the eGFR ≥ 60 mL/min/1.73 m2 but elevated UACR

@escardio #ESCCongress @ESC_Journals @lamcardio @FaiezZANNAD

Read 4 tweets

Henry Han, MBBS, MD

@HanCardiomd

28 Aug

@JavedButler1

SGLT2 Inhibitor HFpEF Data: From Context to Clinical Pearls
By @JavedButler1

#ESCCongress @lamcardio @BSHeartFailure @JJheart_doc @ESC_Journals @ESC_Lavinia @escardio @MKIttlesonMD @ShelleyZieroth @hvanspall @mmamas1973 @aayshacader @pabeda1

@ESC_Lavinia

The drug ⬇️ the risk of ≥ 50% ⬇️ in eGFR or renal death in EMPEROR-Reduced (HR 0.51; 95% CI 0.33-0.79), but not in EMPEROR-Preserved (HR 0.95; 95% CI 0.73-1.24) #ESCCongress @ESC_Lavinia @escardio